Artirat Charukitpipat, PhD, Chief Executive Officer of Bumrungrad International Hospital, revealed that Bumrungrad has successfully achieved its target to expand its patient base to cover Laos, Myanmar, and Vietnam (LMV), Bangladesh, China, the United States, and the Middle East — including the United Arab Emirates, Qatar, and people from these markets are also continuously seeking elective treatment. Through Bumrungrad’s investments in innovative, modern, and world-class medical technology, it can deliver the highest quality care to over 1.1 million Thai and international patients from 190 countries worldwide each year.
“Quality and safety are key to building trust and driving long-term growth. Our success in expanding the patient base is reflected in the remarkable recovery of our Middle Eastern patient base. Revenue from this market grew by 23%, quarter-on-quarter in Q1 2025, particularly the Saudi Arabia (+54% QOQ), the United Arab Emirates (+46% QOQ), Oman (+28% QOQ), and Qatar (+18% QOQ) markets.”
Bumrungrad International Hospital is also investing in accommodating its growing number of patients. The Bumrungrad International Hospital Phuket project is currently under construction and progressing steadily. It is estimated to cost over 4.3 billion THB and should be ready to open by the end of 2027. It will accommodate international patients from all kinds; it will accommodate those seeking treatment for general illnesses as well as those seeking wellness tourism. Bumrungrad International Hospital Phuket will also be a referral center for patients seeking treatment for complex illnesses in Bangkok. Lastly, the Comprehensive Cancer Center at Bumrungrad International Hospital — currently under construction — will be able to accommodate and care for its growing number of patients. It is also expected to open in 2027.
“Bumrungrad International Hospital continues to develop and invest in innovation and new technologies. We have teamed up with the VitalLife Scientific Wellness Center to penetrate the wellness market and deliver seamless, holistic healthcare. We also continue to forge strategic partnerships to provide comprehensive healthcare solutions across industries, including insurance, banking, and real estate. This integration allows Bumrungrad to go beyond treatment into preventive medicine to promote health, longevity, and quality lifestyles, which addresses the future medical trends,” said Artirat Charukitpipat, PhD.
Bumrungrad Hospital Public Company Limited (BH) reported strong, continued growth in its second quarter of 2025, with a core operating EBITDA margin rising to 41.6%. This is a record high for the company and reflects excellent cost control and management effectiveness.
The company announced a 2 baht per share dividend for the first half of 2025, representing 44% of net profit per share, up from 41% in the same period of 2024. Between July 23, 2025 and August 1, 2025, Bumrungrad International Hospital’s share price increased by 16%, with a total trading volume of over 52 million shares (data from the Stock Exchange of Thailand).
Throughout the past 45 years, Bumrungrad has continued to reinforce its leadership position in the healthcare field, as shown by having received many prestigious awards over the years. Bumrungrad has been ranked the number one hospital in Thailand by Newsweek and Statista for five consecutive years, and is the only Thai hospital to be included on their World’s Best Hospitals rankings for five consecutive years (2021-2025). This year, Bumrungrad moved up to 100th place globally from 130th place the year prior. It was also ranked on Newsweek’s Asia’s Top Private Hospitals 2025 list and Best Specialized Hospitals Asia Pacific 2025 list. This achievement demonstrates the successful implementation of its strategy and helps to reinforce Thailand’s reputation as a top international medical and wellness destination.
Symbol: BH